Search

Displaying results 1711 - 1720 of 4262 in total
  1. Drug

    Lormetazepam

    go.drugbank.com/drugs/DB13872
    Approved

    It is marketed by Auden Mckenzie (Pharma Division) in 0.5 and 1 mg tablet formulations.

  2. Drug

    Flufenamic acid

    go.drugbank.com/drugs/DB02266
    Approved

    It is used in musculoskeletal and joint disorders and administered by mouth and topically. (From Martindale, The Extra Pharmacopoeia, 30th ed, p16)

  3. Drug

    Ripretinib

    go.drugbank.com/drugs/DB14840
    ApprovedInvestigational

    Ripretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved by the FDA on May 15, 2020.

  4. Drug

    Human papillomavirus type 52 L1 capsid protein antigen

    go.drugbank.com/drugs/DB10313
    ApprovedInvestigational

    (VLPs) of the major capsid (L1) protein of HPV Type 52 which are produced by separate fermentations in recombinant *Saccharomyces cerevisiae* and self-assembled into VLPs. … It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) type 52 The vaccine is prepared from the purified virus-like particles

  5. Drug

    Tetraethylammonium

    go.drugbank.com/drugs/DB08837
    Investigational

    The only marketed drug containing tetraethylammonium was a combination drug called Fosglutamina B6, but this drug has now been discontinued. … Because of its inhibitory actions at the autonomic ganglia, tetraethylammonium was thought to be a potential therapeutic vasodilator but serious toxic effects were found.

  6. Drug

    Plasma protein fraction (human)

    go.drugbank.com/drugs/DB13968
    ApprovedInvestigational

    [A32512] It is already reviewed under the category of biologics by the FDA where the processing, required tests, requirements and labeling are incorporated.

  7. Drug

    Dermatophagoides farinae

    go.drugbank.com/drugs/DB10400
    ApprovedInvestigational

    Dermatophagoides farinae extracts are sterile solutions used for intradermal testing or subcutaneous immunotherapy. This combination is approved for as a year-round, once-a-day tablet that's dissolved under the tongue as a treatment for ...

  8. Drug

    Dermatophagoides pteronyssinus

    go.drugbank.com/drugs/DB10401
    ApprovedInvestigational

    Dermatophagoides pteronyssinus extracts are sterile solutions used for intradermal testing or subcutaneous immunotherapy. This combination is approved for as a year-round, once-a-day tablet that's dissolved under the tongue as a treatmen...

  9. Drug

    Selinexor

    go.drugbank.com/drugs/DB11942
    ApprovedInvestigational

    [L7117,L7120,L10145] This condition is typically treated with high dose [bortezomib] and [dexamethasone] chemotherapy followed by an autologous stem-cell transplant. … [L10145] The use of selinexor in combination with [bortezomib] and [dexamethasone] was approved by Health Canada in June 2022 for the treatment of multiple myeloma in adult patients who have received at

  10. Drug

    Efgartigimod alfa

    go.drugbank.com/drugs/DB15270
    ApprovedInvestigational

    Myasthenia gravis (MG) is an autoimmune disorder characterized by significant muscle weakness - particularly in the eye, throat, and extremities - caused by autoantibodies attacking the neuromuscular junction … [L39509] By antagonizing this interaction, efgartigimod alfa prevents this recycling phase and thus decreases the half-life of IgG, effectively lowering circulating levels of IgG autoantibodies against